Phase II randomized study of plitidepsin (aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma

Marine Drugs

Volumn 7, Issue 1, 2009, Pages 57-70

  Schöffski, Patrick ^a   Guillem, Vincente ^b   Garcia, Margarita ^c   Rivera, Fernando ^d   Tabernero, Josep ^e   Cullell, Martin ^f   Lopez Martin, Jose Antonio ^f   Pollard, Patricia ^g   Dumez, Herlinde ^a   Del Muro, Xavier Garcia ^c   Paz Ares, Luis ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f PHARMAMAR S A   (Spain)

^g NDDO Oncology   (Netherlands)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Aplidin; L carnitine; Plitidepsin; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARNITINE; CREATINE KINASE; DEHYDRODIDEMNIN B; DEXAMETHASONE; METOCLOPRAMIDE; PLITIDEPSIN; SETRONE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HICCUP; HUMAN; INCIDENCE; INJECTION SITE REACTION; INOPERABLE CANCER; KIDNEY CARCINOMA; LIVER TOXICITY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT INFECTION; SIDE EFFECT; STOMATITIS; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT;

EID: 63049135328     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md7010057     Document Type: Article

References (25)

1. Cancer Facts & Figures - 1996; American Cancer Society: Atlanta, GA, 1996.
2. Linehan, W.M.; Shipley, W.; Parkinson, D. Cancer of the kidney and ureter. In Cancer: Principles and Practice of Oncology, 5th Ed; De Vita, V.T.J., Hellman, S., Rosenberg, S.A., Eds.; Lippincott-Raven: Philadelphia, PA, 1997; pp.1271-1300.
3. Maher, E.R.; Iselius, L.; Yates, J.R.; Littler, M.; Benjamin, C.; Harris, R.; Sampson, J.; Williams, A.; Ferguson-Smith, M.A.; Morton, N. Von Hippel-Lindau disease: a genetic study. J. Med. Genet. 1991, 28, 443-447.
4. Pisters, L.L.; El-Naggar, A.K.; Luo, W.; Malpica, A.; Lin, S.H. C-met proto-oncogene expression in benign and malignant human renal tissues. J. Urol. 1997, 158, 724-728.
5. Gnarra, J.R.; Zhou, S.; Merrill, M.J.; Wagner, J.R.; Krumm, A.; Papavassiliou, E.; Oldfield, E.H.; Klausner, R.D.; Linehan, W.M. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. USA 1996, 93, 10589-10594.
6. Sene, A.P.; Hunt, L.; McMahon, R.F.; Carroll, R.N. Renal carcinoma in patients undergoing nephrectomy: analysis of survival and prognostic factors. Br. J. Urol. 1992, 70, 125-134.
7. Motzer, R.J.; Bander, N.H.; Nanus, D.M. Renal-cell carcinoma. N. Engl. J. Med. 1996, 335, 865-875.
8. Negrier, S.; Escudier, B.; Lasset, C.; Douillard, J.Y.; Savary, J.; Chevreau, C.; Ravaud, A.; Mercatello, A.; Peny, J.; Mousseau, M.; Philip, T.; Tursz, T. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N. Engl. J. Med. 1998, 338, 1272-1278.
9. Bukowski, R.M. Natural history and therapy of metastatic RCC: the role of interleukin-2. Cancer 1997, 80, 1198-1220.
10. Rosenberg, S.A.; Lotze, M.T.; Muul, L.M.; Chang, A.E.; Avis, F.P., Leitman, S.; Linehan, W.M.; Robertson, C.N.; Lee, R.E.; Rubin, J.T.; et al.. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. 1987, 316, 889-897.
11. Biscadi, M.; Caporale, R.; Balestri, F.; Gavazzi, S.; Jimeno, J.; Grossi A. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann. Oncol. 2005, 16, 1667-1674.
12. Faircloth G, Rinehart K, Nunez DC. Dehydrodidemnin B a new marine derived antitumor agent with activity against experimental tumor models. Ann. Oncol. 1996, 7, 34.
13. Casciari, J.J.; Hollingshead, M.G.; Alley, M.C.; Mayo, J.G.; Malspeis, L.; Miyauchi, S.; Grever, M.R.; Weinstein, J.N. Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model. J. Natl. Cancer Inst. 1994, 86, 1846-1852.
14. Anthoney, A.; Paz-Ares, L.; Twelves, C. Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-hour, weekly schedule. Proc. Am. Soc. Clin. Oncol. 2000, 734.
15. Izquierdo, M.A.; Bowman, A.; Garcia, M.; Jodrell, D.; Martinez, M.; Pardo, B.; Gómez, J.; López-Martin, J.A.; Jimeno, J.; Germá, J.R.; Smyth, J.F. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14, 3105-3112.
16. Faivre, S.; Chièze, S.; Delbaldo, C.; Ady-Vago, N.; Guzman, C.; Lopez-Lazaro, L.; Lozahic, S.; Jimeno, J.; Pico, F.; Armand, J.P.; Martin, J.A.; Raymond, E. Phase I and pharmacokinetic study of aplidine aplidine, a new marine cyclodepsipeptide, in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 7780-7782.
17. Maroun, J.A.; Belanger, K.; Seymour, L.; Ady-Vago, N.; Guzman, C; Lopez-Lazaro, L.; Lozahic, S.; Jimeno, J.; Pico, F.; Armand, J.P.; Martin, J.A.; Raymond, E. Phase I study of Aplidine in a dailyx5 one hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy.A National Cancer Institute of Canada Clinical Tirals Group Study : NCIC CTG IND 115. Ann. Oncol. 2006, 17, 1371-1378.
18. Cumming, W.J.; Hardy, M.; Hudgson, P.; Walls, J. Carnitine-palmityl- transferase deficiency. J. Neurol. Sci. 1976, 30, 247-258.
19. Brugarolas, J. Renal-cell carcinoma - molecular pathways and therapies. N. Engl. J. Med. 2007, 356, 185-187.
20. Speca, J.; Yenser, S.; Creel, P.; George, D. Improving outcomes with novel therapies for patients with newly diagnosed RCC. Clin. Genitourin Cancer 2006, 5(Suppl 1), 24-30.
21. Rock, E.P.; Goodman, V.; Jiang, J.X.; Mahjoob, K.; Verbois, S.L.; Mors, D.; Dagher, R.; Justice, R.; Pazdur R. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced RCC. Oncologist 2007, 12, 107-113.
22. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N.; AVOREN Trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma : a randomised, double-blind phase III trial. Lancet 2007, 370, 2103-2111.
23. Atkins, M.B.; Regan, M.; McDermott, D.F. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin. Cancer Res. 2004, 10, 6342-6346.
24. McDermott, D.F.; Atkins, M.B. Application of IL-2 and other cytokines in RCC. Expert Opin. Biol. Ther. 2004, 4, 455-468.
25. Atkins, M.B.; Hidalgo, M.; Stadler, W.M.; Loga, T.F.; Dutcher, J.P.; Hudes, G.R.; Park, Y.; Liou, S.H.; Marshall, B.; Boni, J.P.; Dukart, G.; Sherman, M.L. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory RCC. J. Clin. Oncol. 2004, 22, 909-918.